Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Analytical Performance Evaluation of Whole Genome Sequencing as First-line Genetic Testing for Intellectual Development Disorders and Congenital Malformations

ACMG Annual Clinical Genetics meeting 2025

American College of Medical Genetics

Los Angeles, CA, Mar 18-21 , 2025

Poster presentation: Analytical Performance Evaluation of Whole Genome Sequencing as First-line Genetic Testing for Intellectual Development Disorders and Congenital Malformations

Authors: Bui P, Cain C, Cox J, Fleharty M, Gao Y, Hilton B, Hofherr S, Larkin K, Li G, Marsh D, South S, Toydemir R

Specialty: Genetics

Related content

The Utility of Exome Sequencing for Neurodevelopmental Disorders at a Large Reference Laboratory
Next-Generation Sequencing-Based Panel Testing Identifies Heterogeneous Genetic Etiologies of Short Stature
Audio Podcast
Patient-minded Neurology
Publication
Current State of Pediatric Reference Intervals and the Importance of Correctly Describing the Biochemistry of Child Development: A Review

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.